JP5306208B2 - エンドセリンアゴニストの投与による放射線療法への腫瘍細胞の感作 - Google Patents
エンドセリンアゴニストの投与による放射線療法への腫瘍細胞の感作 Download PDFInfo
- Publication number
- JP5306208B2 JP5306208B2 JP2009526850A JP2009526850A JP5306208B2 JP 5306208 B2 JP5306208 B2 JP 5306208B2 JP 2009526850 A JP2009526850 A JP 2009526850A JP 2009526850 A JP2009526850 A JP 2009526850A JP 5306208 B2 JP5306208 B2 JP 5306208B2
- Authority
- JP
- Japan
- Prior art keywords
- radiation therapy
- patient
- administration
- composition
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001959 radiotherapy Methods 0.000 title claims description 108
- 108050009340 Endothelin Proteins 0.000 title claims description 45
- 102000002045 Endothelin Human genes 0.000 title claims description 45
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title claims description 45
- 239000000556 agonist Substances 0.000 title description 60
- 210000004881 tumor cell Anatomy 0.000 title description 7
- 206010070834 Sensitisation Diseases 0.000 title description 4
- 230000008313 sensitization Effects 0.000 title description 4
- 108010091477 IRL 1620 Proteins 0.000 claims description 38
- DXPHNGAMYPPTBJ-TZMIJSMNSA-N irl 1620 Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CCC(O)=O)C(C)C)C1=CN=CN1 DXPHNGAMYPPTBJ-TZMIJSMNSA-N 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 37
- 206010025323 Lymphomas Diseases 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 239000000018 receptor agonist Substances 0.000 claims description 10
- 229940044601 receptor agonist Drugs 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 8
- 230000002601 intratumoral effect Effects 0.000 claims description 7
- 238000001361 intraarterial administration Methods 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 230000009885 systemic effect Effects 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 73
- 230000005855 radiation Effects 0.000 description 23
- 238000000034 method Methods 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 9
- 230000001235 sensitizing effect Effects 0.000 description 9
- KIYSPBOGUDIMPC-SCGUGKIPSA-N 4-ala-endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)OC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)OC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)C1C=NC=N1 KIYSPBOGUDIMPC-SCGUGKIPSA-N 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000000637 radiosensitizating effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 208000007766 Kaposi sarcoma Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 101710205037 Sarafotoxin Proteins 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000002534 radiation-sensitizing agent Substances 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000011292 agonist therapy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 201000010893 malignant breast melanoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82419706P | 2006-08-31 | 2006-08-31 | |
| US60/824,197 | 2006-08-31 | ||
| PCT/US2007/076903 WO2008027839A1 (en) | 2006-08-31 | 2007-08-27 | Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010502638A JP2010502638A (ja) | 2010-01-28 |
| JP2010502638A5 JP2010502638A5 (enExample) | 2011-07-28 |
| JP5306208B2 true JP5306208B2 (ja) | 2013-10-02 |
Family
ID=38920900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526850A Expired - Fee Related JP5306208B2 (ja) | 2006-08-31 | 2007-08-27 | エンドセリンアゴニストの投与による放射線療法への腫瘍細胞の感作 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8394757B2 (enExample) |
| EP (1) | EP2059254B1 (enExample) |
| JP (1) | JP5306208B2 (enExample) |
| KR (1) | KR101547361B1 (enExample) |
| CN (1) | CN101534852B (enExample) |
| BR (1) | BRPI0722292A2 (enExample) |
| CA (1) | CA2661833C (enExample) |
| DK (1) | DK2059254T3 (enExample) |
| ES (1) | ES2541657T3 (enExample) |
| IL (1) | IL197335A (enExample) |
| MX (1) | MX2009002308A (enExample) |
| NO (1) | NO20091203L (enExample) |
| RU (1) | RU2009111605A (enExample) |
| WO (1) | WO2008027839A1 (enExample) |
| ZA (1) | ZA200901425B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
| WO2008027839A1 (en) | 2006-08-31 | 2008-03-06 | Spectrum Pharmaceuticals, Inc. | Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
| EP2187948A2 (en) * | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Use of a peptide as a therapeutic agent |
| WO2010017332A2 (en) * | 2008-08-07 | 2010-02-11 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Radioprotectants targeting thrombospondin-1 and cd47 |
| US9308235B2 (en) | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
| US10323150B2 (en) | 2015-09-25 | 2019-06-18 | Nippon Kayaku Kabushiki Kaisha | Azo compound, ink composition, ink jet recording method, and colored article |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112954A (en) * | 1988-02-26 | 1992-05-12 | Neorx Corporation | Method of enhancing the effect of cytotoxic agents |
| US5550110A (en) | 1992-04-22 | 1996-08-27 | Warner-Lambert Company | Endothelin Antagonists II |
| CA2135151A1 (en) | 1993-11-08 | 1995-05-09 | Mitsuhiro Wakimasu | Cyclic hexapeptides, their production and use |
| US5811416A (en) | 1994-06-06 | 1998-09-22 | Board Of Regents The University Of Texas System | Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| AU686018B2 (en) | 1994-09-20 | 1998-01-29 | Amcor Packaging (New Zealand) Limited | A container |
| EP0799051B1 (en) | 1994-12-12 | 2005-07-27 | Omeros Corporation | Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound |
| EP0815870A3 (en) | 1996-06-27 | 2000-05-03 | Takeda Chemical Industries, Ltd. | Composition for prohylaxis or treatment of cerebral infarction |
| CA2268640A1 (en) | 1998-04-14 | 1999-10-14 | Mitsuru Shiraishi | Composition for preventing or treating ischemic disease |
| WO2000018393A1 (en) * | 1998-09-25 | 2000-04-06 | Warner-Lambert Company | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
| GB9910155D0 (en) | 1999-04-30 | 1999-06-30 | Microbiological Research Agenc | Augmented agglutination assay |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| US6545048B1 (en) | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| US6635677B2 (en) * | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| EP1289558A2 (en) | 2000-05-31 | 2003-03-12 | Warner-Lambert Company Llc | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| WO2002049630A2 (en) | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
| US20030104976A1 (en) | 2001-07-23 | 2003-06-05 | Gudarz Davar | Analgesic methods using endothelin receptor ligands |
| US7973064B2 (en) | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
| US20030229004A1 (en) * | 2002-03-20 | 2003-12-11 | Pangene Corporation | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
| US20040138121A1 (en) | 2002-10-24 | 2004-07-15 | Anil Gulati | Method and composition for preventing and treating solid tumors |
| US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
| US8217010B2 (en) | 2002-10-24 | 2012-07-10 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| EP1819367B1 (en) * | 2004-11-22 | 2013-11-20 | The Board Of Trustees Of The University Of Illinois | Use of the endothelin etb receptor agonists irl-1620 in tumor imaging |
| CA2598439A1 (en) | 2005-02-22 | 2006-08-31 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| WO2008027839A1 (en) | 2006-08-31 | 2008-03-06 | Spectrum Pharmaceuticals, Inc. | Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
-
2007
- 2007-08-27 WO PCT/US2007/076903 patent/WO2008027839A1/en not_active Ceased
- 2007-08-27 US US11/845,648 patent/US8394757B2/en not_active Expired - Fee Related
- 2007-08-27 JP JP2009526850A patent/JP5306208B2/ja not_active Expired - Fee Related
- 2007-08-27 CN CN200780032550XA patent/CN101534852B/zh not_active Expired - Fee Related
- 2007-08-27 KR KR1020097006395A patent/KR101547361B1/ko not_active Expired - Fee Related
- 2007-08-27 MX MX2009002308A patent/MX2009002308A/es active IP Right Grant
- 2007-08-27 EP EP07841411.7A patent/EP2059254B1/en not_active Not-in-force
- 2007-08-27 DK DK07841411.7T patent/DK2059254T3/en active
- 2007-08-27 RU RU2009111605/15A patent/RU2009111605A/ru not_active Application Discontinuation
- 2007-08-27 ES ES07841411.7T patent/ES2541657T3/es active Active
- 2007-08-27 CA CA2661833A patent/CA2661833C/en active Active
- 2007-08-27 BR BRPI0722292-0A patent/BRPI0722292A2/pt not_active IP Right Cessation
-
2009
- 2009-02-27 ZA ZA200901425A patent/ZA200901425B/xx unknown
- 2009-03-01 IL IL197335A patent/IL197335A/en active IP Right Grant
- 2009-03-23 NO NO20091203A patent/NO20091203L/no not_active Application Discontinuation
-
2013
- 2013-02-06 US US13/761,043 patent/US8957014B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR101547361B1 (ko) | 2015-08-25 |
| ZA200901425B (en) | 2010-04-28 |
| CN101534852A (zh) | 2009-09-16 |
| CA2661833C (en) | 2016-01-26 |
| DK2059254T3 (en) | 2015-07-13 |
| US20080318846A1 (en) | 2008-12-25 |
| US8394757B2 (en) | 2013-03-12 |
| EP2059254A1 (en) | 2009-05-20 |
| JP2010502638A (ja) | 2010-01-28 |
| WO2008027839A1 (en) | 2008-03-06 |
| US20130150649A1 (en) | 2013-06-13 |
| ES2541657T3 (es) | 2015-07-23 |
| EP2059254B1 (en) | 2015-04-08 |
| KR20090069279A (ko) | 2009-06-30 |
| IL197335A (en) | 2013-07-31 |
| RU2009111605A (ru) | 2010-10-10 |
| NO20091203L (no) | 2009-03-23 |
| CN101534852B (zh) | 2013-02-13 |
| CA2661833A1 (en) | 2008-03-06 |
| MX2009002308A (es) | 2009-09-07 |
| BRPI0722292A2 (pt) | 2014-04-15 |
| IL197335A0 (en) | 2011-08-01 |
| US8957014B2 (en) | 2015-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5306208B2 (ja) | エンドセリンアゴニストの投与による放射線療法への腫瘍細胞の感作 | |
| JP2010095547A (ja) | 固形腫瘍を予防および治療するための方法および組成物 | |
| EP2046323B1 (en) | Compositions for contributing to the treatment of cancers | |
| US20060211617A1 (en) | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors | |
| KR20190084291A (ko) | 암 치료를 위한 제약 조성물 및 방법 | |
| JP2012214519A (ja) | 固形腫瘍の治療に貢献するための方法、組成物及び製品 | |
| US8642026B2 (en) | Methods and compositions for contributing to the treatment of cancers | |
| RU2314807C2 (ru) | Комбинированная противоопухолевая терапия, включающая использование замещенных акрилоилпроизводных дистамицина и лучевой терапии | |
| EP2144607B1 (en) | Compositions for contributing to the treatment of cancers | |
| AU2008240300B2 (en) | Methods and compositions for contributing to the treatment of cancers | |
| HK1129601B (en) | Compositions for contributing to the treatment of cancers | |
| HK1140145B (en) | Compositions for contributing to the treatment of cancers | |
| EA042139B1 (ru) | Фармацевтические композиции и способы лечения рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100624 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110606 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120724 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121010 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121010 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130308 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130528 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130625 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5306208 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |